trending Market Intelligence /marketintelligence/en/news-insights/trending/_Qks4fqRVM7e3lEirolaYg2 content esgSubNav
In This List

Genmab Q2 after-tax profit declines YOY; revenue outlook raised

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Genmab Q2 after-tax profit declines YOY; revenue outlook raised

Genmab A/S said its after-tax profit for the second quarter of 2019 declined year over year and updated its revenue outlook for the full year.

After-tax profit totaled 84.9 million Danish kroner, down from 260.5 million kroner in the year-earlier period. EPS came in at 1.35 kroner, a decline from 4.21 kroner in the prior-year period.

The S&P Global Market Intelligence consensus normalized estimate for the quarter was 1.09 kroner.

The Danish company, which develops cancer treatments, said its revenue grew year over year to 773.9 million kroner from 509.7 million kroner.

Genmab's research and development expenses rose to 563.4 million kroner in the second quarter from 318.9 million kroner in the year-earlier period.

Copenhagen-based Genmab also increased its revenue guidance for the year to 4.80 billion kroner from the previous guidance of 4.60 billion kroner. Additionally, it also revised its operating income outlook for 2019 to 2.05 billion kroner from the previous guidance of 2 billion kroner.

As of Aug. 13, US$1 was equivalent to 6.67 Danish kroner.